Apr 15, 2026 08:31AM
Apr 15, 2026 08:30AM
Apr 13, 2026 11:13AM
Jan 12, 2026 10:14AM
Dec 15, 2025 05:40PM
Dec 15, 2025 05:39PM
Nov 6, 2025 04:05PM Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
Nov 3, 2025 09:04AM
Aug 13, 2025 04:05PM
Aug 1, 2025 08:31AM
Aug 1, 2025 08:30AM
Jun 1, 2025 10:45AM
May 22, 2025 05:21PM
May 22, 2025 05:17PM Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Apr 23, 2025 10:12AM
Apr 7, 2025 08:31AM
Apr 7, 2025 08:30AM
Mar 13, 2025 04:02PM
Feb 25, 2025 04:11PM
Feb 25, 2025 04:10PM
Feb 13, 2025 04:30PM Allogene Therapeutics (ALLO) Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials
Feb 13, 2025 04:30PM
Jan 28, 2025 08:31AM
Jan 28, 2025 08:30AM
Jan 2, 2025 04:00PM
Nov 18, 2024 08:37AM
Nov 18, 2024 08:30AM
Nov 7, 2024 04:02PM Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Nov 7, 2024 10:00AM
Nov 7, 2024 10:00AM
Nov 5, 2024 09:10AM
Oct 30, 2024 08:14AM
Oct 29, 2024 08:30AM
Oct 29, 2024 08:30AM
Sep 26, 2024 08:33AM Allogene Therapeutics (ALLO) to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases
Sep 26, 2024 08:30AM
Aug 7, 2024 04:02PM
Jul 1, 2024 08:30AM
Jun 20, 2024 08:30AM
May 13, 2024 04:01PM
Apr 26, 2024 08:32AM
Apr 26, 2024 08:30AM Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Apr 26, 2024 08:30AM
Mar 14, 2024 04:05PM
Mar 12, 2024 08:30AM
Mar 12, 2024 08:30AM
Jan 4, 2024 04:16PM
Jan 4, 2024 04:15PM
Jan 4, 2024 04:08PM Allogene Therapeutics (ALLO) Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3
Jan 4, 2024 04:05PM

322,206 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All